Nanobiotix
- Country
- 🇫🇷France
- Ownership
- -
- Employees
- 102
- Market Cap
- -
- Introduction
Nanobiotix SA is a late-stage biotechnology company, which engages in the development of therapeutic approaches to the treatment of cancer. Its technologies include NanoXray that improves the efficacy of radiation therapy against tumor cells. The company was founded by Laurent Lévy and Abdel Kader Boussaha on March 4, 2003 and is headquartered in Paris, France.
JNJ-90301900 (NBTXR3) Activated by Radiotherapy With or Without Cetuximab in LA-HNSCC
- Conditions
- Locally Advanced Head and Neck Squamous Cell CarcinomaAged
- Interventions
- First Posted Date
- 2021-05-19
- Last Posted Date
- 2025-04-03
- Lead Sponsor
- Johnson & Johnson Enterprise Innovation Inc.
- Target Recruit Count
- 500
- Registration Number
- NCT04892173
- Locations
- 🇮🇳
Apollo Speciality Hospital, Chennai, Chennai, India
🇮🇳Meenakshi Mission Hospital and Research Center, Madhurai, India
🇪🇸Hosp. Gral. Univ. Valencia, Valencia, Spain
NBTXR3 Activated by Radiotherapy for Patients with Advanced Cancers Treated with an Anti-PD-1 Therapy
- Conditions
- RadiotherapyImmunotherapyMicrosatellite Instability-High Solid Malignant TumourMetastasis from Malignant Tumor of LiverSquamous Cell Carcinoma of Head and NeckMetastasis from Malignant Tumor of CervixMetastasis from Malignant Melanoma of Skin (disorder)Metastatic Triple-Negative Breast CarcinomaMetastatic NSCLCMetastatic Renal Cell Carcinoma
- Interventions
- First Posted Date
- 2018-07-17
- Last Posted Date
- 2025-01-14
- Lead Sponsor
- Nanobiotix
- Target Recruit Count
- 145
- Registration Number
- NCT03589339
- Locations
- 🇺🇸
Christus St. Vincent Regional Cancer Center, Santa Fe, New Mexico, United States
🇺🇸St Luke's University Health Network, Bethlehem, Pennsylvania, United States
🇺🇸Sanford Cancer Center, Sioux Falls, South Dakota, United States
NBTXR3 Nanoparticles and EBRT or EBRT With Brachytherapy in the Treatment of Prostate Adenocarcinoma
- Conditions
- Prostate Cancer
- Interventions
- Drug: NBTXR3 activated by IMRT onlyDrug: NBTXR3 activated by Brachytherapy & IMRT
- First Posted Date
- 2016-06-20
- Last Posted Date
- 2021-05-10
- Lead Sponsor
- Nanobiotix
- Target Recruit Count
- 5
- Registration Number
- NCT02805894
- Locations
- 🇺🇸
Thomas Jefferson University Hospital, Philadelphia, Pennsylvania, United States
🇺🇸Dana Farber Cancer Institute/Brigham and Women's Hospital, Boston, Massachusetts, United States
NBTXR3 Crystalline Nanoparticles and Stereotactic Body Radiation Therapy in the Treatment of Liver Cancers
- Conditions
- Liver Cancer
- Interventions
- Radiation: NBTXR3, IL or IA injection + SBRT
- First Posted Date
- 2016-03-28
- Last Posted Date
- 2021-05-10
- Lead Sponsor
- Nanobiotix
- Target Recruit Count
- 23
- Registration Number
- NCT02721056
- Locations
- 🇫🇷
Centre René Gauducheau, Nantes, France
🇫🇷Institut de Cancérologie de Loraine, Nancy, France
🇫🇷Hôpital Haut-Lévêque, Pessac, France
NBTXR3 Crystalline Nanoparticles and Radiation Therapy in Treating Randomized Patients in Two Arms With Soft Tissue Sarcoma of the Extremity and Trunk Wall
- Conditions
- Adult Soft Tissue Sarcoma
- Interventions
- Device: Radiation therapyDevice: NBTXR3
- First Posted Date
- 2015-03-05
- Last Posted Date
- 2021-04-06
- Lead Sponsor
- Nanobiotix
- Target Recruit Count
- 180
- Registration Number
- NCT02379845
- Locations
- 🇦🇺
Chris O'Brien Lifehouse, Sydney, Australia
🇦🇺Capital Region Cancer Service, Canberra Hospital, Canberra, Australia
🇧🇪Jules Bordet Institute, Bruxelles, Belgium
NBTXR3 and Radiation Therapy in Treating Patients With Locally Advanced SCC of the Oral Cavity or Oropharynx
- Conditions
- Head and Neck Cancer
- Interventions
- Device: NBTXR3 activated by IMRT
- First Posted Date
- 2013-09-20
- Last Posted Date
- 2022-12-29
- Lead Sponsor
- Nanobiotix
- Target Recruit Count
- 75
- Registration Number
- NCT01946867
- Locations
- 🇭🇺
Hungarian Defense Forces Hospital, Budapest, Hungary
🇪🇸Hospital Fundación Jimenez Diaz, Madrid, Spain
🇵🇱Centrum Onkologii - Instytut im. M. Skłodowskiej- Curie, Oddział w Gliwicach, Gliwice, Poland
NBTXR3 Crystalline Nanoparticles and Radiation Therapy in Treating Patients With Soft Tissue Sarcoma of the Extremity
- Conditions
- Adult Soft Tissue Sarcoma
- Interventions
- Device: NBTXR3
- First Posted Date
- 2011-09-13
- Last Posted Date
- 2020-10-06
- Lead Sponsor
- Nanobiotix
- Target Recruit Count
- 22
- Registration Number
- NCT01433068
- Locations
- 🇫🇷
Institut Bergonie, Bordeaux, France
🇫🇷Institut Gustave Roussy, Villejuif, France